Association between medical androgen deprivation therapy and long-term cardiovascular disease and all-cause mortality in nonmetastatic prostate cancer
- PMID: 35489025
- PMCID: PMC9544783
- DOI: 10.1002/ijc.34058
Association between medical androgen deprivation therapy and long-term cardiovascular disease and all-cause mortality in nonmetastatic prostate cancer
Erratum in
-
Erratum.Int J Cancer. 2023 Sep 15;153(6):E3. doi: 10.1002/ijc.34613. Epub 2023 Jun 1. Int J Cancer. 2023. PMID: 37264669 Free PMC article. No abstract available.
Abstract
Studies have suggested that prostate cancer (PCa) patients receiving androgen deprivation therapy (ADT) are at increased risk of developing or exacerbating cardiovascular disease (CVD). We aimed to explore the association between ADT for PCa and subsequent CVD and all-cause mortality in this nationwide, longitudinal study. We also evaluated the role of cardiovascular risk and ADT duration to determine effect modification. Norwegian registry data were used to identify patients with PCa from 2008-18 and who received primary ADT in the first year after diagnosis. The associations between ADT and composite cardiovascular events, and the individual components of myocardial infarction, stroke and heart failure, in addition to atrial fibrillation and all-cause mortality, were explored using time-varying Cox regression models. We included 30 923 PCa patients, of whom 8449 (27%) received primary ADT. Mean follow-up was 2.9 and 3.8 years for CVD events and mortality, respectively. We found an association between ADT and composite CVD (adjusted HR 1.13: 95% CI 1.05-1.21), myocardial infarction (1.18: 1.05-1.32), stroke (1.21: 1.06-1.38), heart failure (1.23: 1.13-1.35) and all-cause mortality (1.49: 1.39-1.61). These associations persisted in those with low and moderate CVD risk and ADT longer than 7 months. A relationship between ADT and composite CVD and all-cause mortality was observed, especially in those with moderate CVD risk and longer treatment duration. Future studies with more detailed cancer data are needed to verify the clinical relevance of these results, especially when considering all-cause mortality within the context of treatment guidelines and benefits of ADT.
Keywords: androgen deprivation therapy; cardiovascular disease; epidemiology; prostate cancer.
© 2022 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
Conflict of interest statement
The authors declare no potential conflict of interests.
Figures
Similar articles
-
Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis.Eur Urol. 2015 Sep;68(3):386-96. doi: 10.1016/j.eururo.2014.11.039. Epub 2014 Dec 5. Eur Urol. 2015. PMID: 25484142 Review.
-
Is androgen deprivation therapy for prostate cancer associated with cardiovascular disease? A meta-analysis and systematic review.Andrology. 2020 May;8(3):559-574. doi: 10.1111/andr.12731. Epub 2019 Dec 17. Andrology. 2020. PMID: 31743594
-
Androgen-deprivation therapy and risk of death from cardio-vascular disease in prostate cancer patients: a nationwide lithuanian population-based cohort study.Aging Male. 2022 Dec;25(1):173-179. doi: 10.1080/13685538.2022.2091130. Aging Male. 2022. PMID: 35882633
-
Risk of cardiovascular events following intermittent and continuous androgen deprivation therapy in patients with nonmetastatic prostate cancer.Urol Oncol. 2024 Dec;42(12):447.e1-447.e9. doi: 10.1016/j.urolonc.2024.05.026. Epub 2024 Jul 12. Urol Oncol. 2024. PMID: 39003108
-
Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction.Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):1411-6. doi: 10.1016/j.ijrobp.2011.04.067. Epub 2011 Jun 25. Int J Radiat Oncol Biol Phys. 2012. PMID: 21708431
Cited by
-
Insights Into the Cardiomodulatory Effects of Sex Hormones: Implications in Transgender Care.Hypertension. 2023 Sep;80(9):1810-1820. doi: 10.1161/HYPERTENSIONAHA.123.19501. Epub 2023 Jul 18. Hypertension. 2023. PMID: 37462057 Free PMC article. Review.
-
The Effect of Androgen Deprivation Therapy on the Cardiovascular System in Advanced Prostate Cancer.Medicina (Kaunas). 2024 Oct 22;60(11):1727. doi: 10.3390/medicina60111727. Medicina (Kaunas). 2024. PMID: 39596912 Free PMC article. Review.
-
Erratum.Int J Cancer. 2023 Sep 15;153(6):E3. doi: 10.1002/ijc.34613. Epub 2023 Jun 1. Int J Cancer. 2023. PMID: 37264669 Free PMC article. No abstract available.
-
Comparative Cardiovascular Risks of Radical Prostatectomy and External Beam Radiation Therapy in Early-Stage Prostate Cancer: A Comprehensive Retrospective Analysis.Ann Surg Oncol. 2024 Nov;31(12):8427-8437. doi: 10.1245/s10434-024-15982-7. Epub 2024 Aug 20. Ann Surg Oncol. 2024. PMID: 39164605
-
Comprehensive review of cardiovascular disease in prostate cancer: epidemiology, risk factors, therapeutics and prevention strategies.Prostate Cancer Prostatic Dis. 2024 Nov 6. doi: 10.1038/s41391-024-00897-x. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 39506079 Review.
References
-
- Van Hemelrijck M, Garmo H, Holmberg L, et al. Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the population‐based PCBaSe Sweden. J Clin Oncol. 2010;28:3448‐3456. - PubMed
-
- Azoulay L, Yin H, Benayoun S, Renoux C, Boivin J‐F, Suissa S. Androgen‐deprivation therapy and the risk of stroke in patients with prostate cancer. Eur Urol. 2011;60:1244‐1250. - PubMed
-
- Jespersen CG, Nørgaard M, Borre M. Androgen‐deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a Nationwide Danish population‐based cohort study. Eur Urol. 2014;65:704‐709. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical